Gene Xpert MTB/RIF assay confirms its value in the first multicentre, randomised, controlled trial conducted in primary-care settings in Africa

Comment

Roberto Cauda. Pathog Glob Health. 2014 Apr.

. 2014 Apr;108(3):127.

doi: 10.1179/2047772414Z.000000000200.

No abstract available

Comment on

Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.
Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K; TB-NEAT team. Theron G, et al. Lancet. 2014 Feb 1;383(9915):424-35. doi: 10.1016/S0140-6736(13)62073-5. Epub 2013 Oct 28. Lancet. 2014. PMID: 24176144 Clinical Trial.

1. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy and clinical effects of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383:424–35. - PubMed
1. Churchyard G, McCarthy K, Fielding KL, Stevens W, Chihota V, Nicol M, et al. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: a pragmatic randomized trial. In: Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 3–6 March 2014; Boston, MA, USA. Abstract 95.
1. WHO . Implementation and roll-out of Xpert MTB/RIF May 2013. Update from the STOP TB Department. Vol. 2013 Geneva: World Health Organization;